Cite

    Lin, W. et al. (n.d.). A population‐based nested case–control study: the use of 5‐alpha‐reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia. Clinical endocrinology. pp. 503-508. [Online].